Analyst Reco. Y-mAbs Therapeutics, Inc.

Equities

YMAB

US9842411095

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
17.25 ^USD	+4.61%		+16.24%	+152.93%

Mar. 14	Y-mAbs Therapeutics Chief Financial Officer Bo Kruse to Resign	MT
Mar. 14	Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Adjusts Price Target on Y-mAbs Therapeutics to $22 From $21, Keeps Buy Rating	Mar. 06	MT
Canaccord Genuity Raises Price Target on Y-mAbs Therapeutics to $26 From $22, Maintains Buy Rating	Mar. 04	MT
BMO Capital Adjusts Y-mAbs Therapeutics Price Target to $26 From $16, Maintains Outperform Rating	Mar. 04	MT
Wedbush Raises Y-mAbs Therapeutics' PT to $23 From $18 After Higher-Than-Expected Q4 2023 Danyelza Net Product Revenue, Maintains Outperform Rating	Mar. 04	MT
HC Wainwright Adjusts Y-mAbs Therapeutics Price Target to $21 From $11, Maintains Buy Rating	Feb. 20	MT
Wedbush Raises Price Target on Y-mAbs Therapeutics to $18 From $12 After Plans for Phase 1 Cancer Drug Study, Keeps Outperform Rating	Feb. 12	MT
Kempen Upgrades Y-mAbs Therapeutics to Buy From Neutral, Price Target is $10	Dec. 22	MT
JPMorgan Adjusts Y-mAbs Therapeutics Price Target to $7 From $8, Maintains Underweight Rating	23-08-22	MT
Morgan Stanley Adjusts Price Target on Y-mAbs Therapeutics to $5 From $7, Maintains Underweight Rating	23-08-14	MT
Wedbush Trims Y-mAbs Therapeutics' Price Target to $12 From $13, Keeps Outperform Rating	23-08-11	MT
Canaccord Genuity Adjusts Y-mAbs Therapeutics' Price Target to $22 From $21, Keeps Buy Rating	23-07-25	MT
Morgan Stanley Adjusts Price Target on Y-mAbs Therapeutics to $7 From $4, Maintains Underweight Rating	23-05-10	MT
BMO Capital Raises Y-mAbs Therapeutics' Price Target to $15 From $13, Maintains Outperform Rating	23-05-10	MT
Wedbush Upgrades Y-mAbs Therapeutics to Outperform From Neutral, Notes Danyelza Return to Growth Trajectory; Raises PT to $13 From $5	23-05-10	MT
Canaccord Genuity Adjusts Y-mAbs Therapeutics Price Target to $21 From $18, Maintains Buy Rating	23-05-09	MT
HC Wainwright Lowers Price Target on Y-mAbs Therapeutics to $11 From $19, Maintains Buy Rating	23-04-04	MT
Guggenheim Downgrades Y-mAbs Therapeutics to Neutral From Buy	23-04-03	MT
Canaccord Genuity Adjusts Price Target on Y-mAbs Therapeutics to $18 From $20, Maintains Buy Rating	23-03-31	MT
BMO Capital Adjusts Price Target on Y-mAbs Therapeutics to $13 From $12, Maintains Outperform Rating	23-01-30	MT
Morgan Stanley Downgrades Y-mAbs Therapeutics to Underweight From Equal Weight	23-01-27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Y-mAbs Therapeutics, Inc.

Equities

YMAB

US9842411095

Analyst Reco.

Filters